Any content you receive is for information purposes only. Always conduct your own research.
*Sponsored
Krypton Street Just Put Enlivex (Nasdaq: ENLV) On The Radar
This Morning—Wednesday, August 12, 2026
Don’t Miss Our Next Update—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. Here's Why ENLV Is In Focus This Morning… August 12, 2026 Dear Reader, Good morning. The bell rings in under 90 minutes. Last night, the full picture on Enlivex Ltd. (Nasdaq: ENLV) went out — the FDA RMAT designation for Allocetra, the $400M institutional commitment at $5 and $6 per share, the Rain protocol's $860M in July platform activity — up 622% over June — and a RAIN token treasury valued near $1.1Bn as of July 18, 2026. This morning, ENLV is still the first name on the screen. Here is what matters right now before the open. Fewer than 4M shares are listed as available to the public. According to Benzinga, H.C. Wainwright's Raghuram Selvaraju raised his published Bullish target to $80 last week — against a name that has been near the $2 range. That gap does not shrink overnight. The 182-patient Phase IIb trial is active across three countries. The FDA has requested a Type B meeting following the RMAT designation. And a single institution has $400M committed — with an option to put in another $400M over the next 36 months. The bell rings in under 90 minutes. Pull up ENLV before it does. 
But keep in mind, ENLV has less than 4M shares listed as available to the public right now. When companies have small floats like this, the potential exists for big moves if demand begins to shift. ENLV is currently trending around $2, but according to Benzinga, H.C. Wainwright analyst Raghuram Selvaraju raised his target to $80 last week, highlighting a substantial gap between current levels and his outlook. And there is another part of the ENLV story worth looking at: the company’s balance sheet and reported financial results. Enlivex reported FY2025 net income of $1.23B and diluted EPS of $25.48 — driven largely by appreciation in its RAIN token holdings. Total treasury and derivative assets stood at $2.31B, while shareholders’ equity reached $1.93B. About Enlivex Ltd. (Nasdaq: ENLV)
Enlivex runs two strategies in parallel. The first is a clinical-stage immunotherapy program centered on Allocetra — an off-the-shelf, allogeneic cell therapy that reprograms macrophages back to their homeostatic state to resolve chronic inflammation. The lead indication is age-related primary knee osteoarthritis. The second is a digital asset treasury built around the RAIN protocol on Arbitrum. The active Phase IIb trial targets 182 patients aged 64 and older across the United States, Denmark, and Poland, with top-line data expected in 2027. Following the RMAT grant, the FDA requested a Type B meeting to align on Phase IIb design and late-stage development plans — an early, structured regulatory dialogue that is rare and valuable at this stage of development. By July 18, 2026, Enlivex held approximately 79.55Bn RAIN tokens valued at roughly $1.1Bn, with a reported unaudited mark-to-market NAV per share of $66.16. The company also carries an option on 271.37Bn additional tokens at $0.0033 per token — intrinsic value estimated near $2.23Bn as of May 2026. The Backdrop That Makes ENLV Worth a Closer Look
The RMAT designation fundamentally changes the regulatory calculus for Allocetra. RMAT is not a routine milestone. The FDA grants it only when preliminary clinical evidence suggests a regenerative therapy can address a serious unmet need — and fewer than half of all RMAT applications are approved. That bar is high — and Allocetra cleared it based on Phase IIa data showing statistically significant, durable improvements in pain and function in the 60-plus cohort at three and six months. Osteoarthritis is projected to affect approximately 78M Americans by 2040, according to the CDC. The global osteoarthritis therapeutics market currently sits at $10.84Bn and is projected to reach approximately $26.31Bn by 2035 — a compound annual growth rate of 9.27%. That's the market backdrop. The 64-plus primary OA population — the specific group now targeted in Phase IIb — has no approved disease-modifying therapy within it. Every current pathway is symptomatic. Allocetra's mechanism targets macrophage polarization rather than broadly suppressing immunity, making it a structurally distinct candidate in a category where no approved therapy yet exists. The RAIN protocol side of the ledger is also moving. $860M in Rain protocol activity for July 2026 represents a 622% jump from June. With platform throughput targets of $1.3Bn (2027), $12Bn (2028), and $33Bn (2029), and a buyback-and-burn mechanism projected to generate $24M, $216M, and $600M in net fees at those levels, the structural demand driver for RAIN tokens — and for the treasury ENLV holds — becomes clearer. The NAV-to-market-cap gap remains wide. Readers who understand why it exists are better positioned to evaluate whether it narrows. What Has Happened at ENLV in the Last 90 Days
FDA RMAT Designation for Allocetra (July 13, 2026) — The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to Allocetra for the treatment of age-related symptomatic knee osteoarthritis in patients aged 64 and older. RMAT designation provides intensive, early FDA engagement and eligibility pathways for accelerated approval and priority review. 
Following the designation, the FDA requested a Type B meeting with Enlivex to conduct a comprehensive, multidisciplinary discussion of the Allocetra development program and Phase IIb planning. $400M Institutional Commitment (July 28, 2026) — A single institutional player agreed to purchase $400M of ENLV ordinary shares at $5 per share or $6 per share (RAIN tokens) — premiums of 17.4% and 40.8% to the July 27 close. The company holds an optional right to call an additional $400M from the same counterparty over 36 months. Closing requires shareholder approval. The buyer elected RAIN token funding, which election may be changed before close. RAIN Protocol Activity Reaches $860M (July 30, 2026) — The Rain protocol reported $860M in platform activity for July 2026, a 622% month-over-month increase versus June. Rain Foundation long-range throughput targets: $1.3Bn (2027), $12Bn (2028), $33Bn (2029), with projected buyback-and-burn proceeds of $24M, $216M, and $600M in those respective years. Treasury NAV Per Share of $66.16 (July 20, 2026) — As of July 18, 2026, Enlivex held approximately 79.55Bn RAIN tokens valued at roughly $1.1Bn. Unaudited mark-to-market NAV per ordinary share: $66.16. EULAR 2026 Oral Presentation (June 2026) — Phase IIa Allocetra data was selected for an oral podium presentation at the EULAR European Congress of Rheumatology in London, presented by Prof. Philip Conaghan. Results showed statistically significant and durable pain and function improvements in patients aged 60 and older at three and six months, with a favorable safety profile. Phase IIb First U.S. Patient Dosed (May 2026) — Enlivex dosed the first patient at a U.S. site in its Phase IIb Allocetra trial for age-related knee osteoarthritis. The 182-patient multicenter study spans the United States, Denmark, and Poland, targeting patients aged 64 and older following FDA IND and Danish Medicines Agency clearances. FY2025 Full-Year Results (March 25, 2026) — Net income of $1.23Bn. Diluted EPS of $25.48. Total treasury and derivative assets of $2.31Bn. Shareholders' equity of $1.93Bn. Cash and short-term digital assets of $30.0M as of December 31, 2025. 7 Reasons Why We Have ENLV At The Top Of Our Watchlist This Morning—Wednesday, August 12, 2026…
1. Low Float: With fewer than 4M shares listed as available to the public, ENLV’s small float could have the potential for big moves if demand begins to shift. 2. Analyst Target: With ENLV recently trending around $2, Benzinga reports that H.C. Wainwright analyst Raghuram Selvaraju raised his target to $80, creating a substantial gap between current levels and his published target. 3. FDA Designation: After Allocetra received RMAT designation for age-related knee osteoarthritis in patients 64 and older, ENLV gained access to more intensive FDA engagement and potential accelerated approval pathways. 4. Institutional Commitment: A single institution agreed to a $400M private placement at $5 to $6 per share, giving ENLV a significant proposed capital commitment that remains subject to shareholder approval and closing conditions. 5. RAIN Momentum: Following a reported 622% month-over-month increase to $860M in July platform activity, ENLV has growing exposure to the RAIN ecosystem through its substantial token treasury. 6. Treasury Value: As of July 18, Enlivex reported roughly $1.1B in RAIN holdings and an unaudited mark-to-market NAV of $66.16 per share, giving ENLV an unusual treasury component alongside its clinical program. 7. Clinical Progress: With a 182-patient Phase IIb study underway across the United States, Denmark, and Poland, ENLV has an active late-stage clinical catalyst with top-line data expected in 2027. Here's Why ENLV Is In Focus This Morning…
There is a lot happening around ENLV at the same time, and that combination is what makes it worth keeping on your radar. The company has fewer than 4M shares listed as available to the public, an FDA RMAT designation for Allocetra, a proposed $400M private placement at $5 to $6 per share, and a 182-patient Phase IIb study underway across three countries. Then there is the RAIN side of the story. Enlivex reported roughly $1.1B in RAIN holdings as of July 18, along with an unaudited mark-to-market NAV of $66.16 per share, while Rain protocol platform activity climbed 622% month over month to $860M in July. And with ENLV recently hovering around $2, Benzinga reports that H.C. Wainwright analyst Raghuram Selvaraju raised his target to $80 — a substantial gap that gives readers another reason to study the story closely. None of these developments should be viewed in isolation. Together, they give ENLV several separate areas to watch: regulatory progress, clinical development, proposed financing, a relatively small public float, and a rapidly changing digital-asset treasury. We have all eyes on ENLV this morning. Take a look at ENLV while it’s still early. Sincerely, Alex Ramsay
Co-Founder / Managing Editor
Krypton Street Newsletter |
0 التعليقات:
إرسال تعليق